| 前收市價 | 0.0100 |
| 開市 | 0.0100 |
| 買盤 | 0.0000 |
| 賣出價 | 0.5100 |
| 拍板 | 113.00 |
| 到期日 | 2024-06-28 |
| 今日波幅 | 0.0100 - 0.0100 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 15 |
Investor's Business DailyEli Lilly Has Sprinted 55% Higher This Year — Is It A Buy On The Weight-Loss Opportunity?
Is Eli Lilly stock a buy as it looks to enter the obstructive sleep apnea treatment market? Is LLY stock a buy right now?
BenzingaNovo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Appr
BenzingaNovo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk A/S (NYSE:NVO) plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply. China’s National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese. Also Read: Novo Nordisk’s Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows. Maziar Mike Doustdar, Novo Nordisk’s chief of international operati
